Sulkes A, Livingston R B, Murphy W K
J Natl Cancer Inst. 1979 Mar;62(3):513-5. doi: 10.1093/jnci/62.3.513.
Tumor cell uptake of tritiated thymidine, expressed as the labeling index (Ll), was determined prior to treatment of 25 patients with disseminated breast carcinoma. All patients subsequently received combination chemotherapy with adriamycin, cyclophosphamide, and an antimetabolite (usually 5-fluorouracil), with or without vincristine. The Ll was significantly higher in responders to chemotherapy than in nonresponders (mean, 15 vs. 7.1; P less than 0.01). Other pretreatment variables examined did not show a significant association with likelihood of response. Measurements of the tumor cell Ll in patients with accessible tumor may be of benefit in selection of treatment; 0 of 9 patients with an Ll less than 9 had a response in our series in contrast to 11 of 16 patients with an Ll greater than 9 who had a response (P = 0.001).
在对25例弥漫性乳腺癌患者进行治疗前，测定了肿瘤细胞对氚标记胸腺嘧啶核苷的摄取情况，并以标记指数（LI）表示。所有患者随后均接受了阿霉素、环磷酰胺和一种抗代谢药物（通常为5-氟尿嘧啶）的联合化疗，部分患者还联合或未联合长春新碱。化疗反应者的LI显著高于无反应者（平均值分别为15和7.1；P<0.01）。所检测的其他预处理变量与反应可能性未显示出显著相关性。对可触及肿瘤患者的肿瘤细胞LI进行测量，可能有助于治疗方案的选择；在我们的系列研究中，LI小于9的9例患者均无反应，而LI大于9的16例患者中有11例有反应（P = 0.001）。
